Literature DB >> 10672362

Immunolocalization of the transcription factor Slug in the developing avian heart.

R Carmona1, M González-Iriarte, D Macías, J M Pérez-Pomares, L García-Garrido, R Muñoz-Chápuli.   

Abstract

Slug is a transcription factor involved in processes such as the formation of mesoderm and neural crest, two developmental events that imply a transition from an epithelial to a mesenchymal phenotype. During late cardiac morphogenesis, mesenchymal cells originate from two epithelia--epicardial mesothelium and cushion endocardium. We aimed to check if Slug is expressed in these systems of epithelial-mesenchymal transition. We have immuno-located the Slug protein in the heart of quail embryos between Hamburger and Hamilton stages HH16 and HH30. In the proepicardium (the epicardial primordium), Slug was detected in most cells, mesothelial as well as mesenchymal. Slug immunoreactivity was strong in the mesenchyme of the endocardial cushions and subepicardium from its inception until HH24, but the immunoreactivity disappeared in later embryos. Only a small portion of the endocardial cells located in the areas of epithelial-mesenchymal transition (atrioventricular groove and outflow tract) were immuno-labelled, mainly between HH16 and HH20. Endocardial cells from other cardiac segments were always negative, except for a transient, weak immunoreactivity that coincided with the development of the intertrabecular sinusoids of the ventricle. In contrast, virtually all cells of the epicardial mesothelium were immunoreactive until stage HH24. The mesenchymal cells that migrate to the heart through the spina vestibuli were also conspicuously immunoreactive. The myocardium was not labelled in the stages studied. Our results stress the involvement of Slug in the epithelial to mesenchymal transition. We suggest that Slug can constitute a reliable marker of the cardiac epithelial cells that are competent to transform into mesenchyme as well as a transient marker of the epithelial-derived mesenchymal cells in the developing heart.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10672362     DOI: 10.1007/pl00008230

Source DB:  PubMed          Journal:  Anat Embryol (Berl)        ISSN: 0340-2061


  8 in total

Review 1.  Cellular precursors of the coronary arteries.

Authors:  Ramón Muñoz-Chápuli; Mauricio González-Iriarte; Rita Carmona; Gerardo Atencia; David Macías; José María Pérez-Pomares
Journal:  Tex Heart Inst J       Date:  2002

Review 2.  Heart valve development: endothelial cell signaling and differentiation.

Authors:  Ehrin J Armstrong; Joyce Bischoff
Journal:  Circ Res       Date:  2004-09-03       Impact factor: 17.367

3.  Kaposi sarcoma herpesvirus promotes endothelial-to-mesenchymal transition through Notch-dependent signaling.

Authors:  Paola Gasperini; Georgina Espigol-Frigole; Peter J McCormick; Ombretta Salvucci; Dragan Maric; Thomas S Uldrick; Mark N Polizzotto; Robert Yarchoan; Giovanna Tosato
Journal:  Cancer Res       Date:  2012-01-11       Impact factor: 12.701

Review 4.  Epicardium-derived cells in cardiogenesis and cardiac regeneration.

Authors:  E M Winter; A C Gittenberger-de Groot
Journal:  Cell Mol Life Sci       Date:  2007-03       Impact factor: 9.261

5.  Generation of a functional liver tissue mimic using adipose stromal vascular fraction cell-derived vasculatures.

Authors:  S S Nunes; J G Maijub; L Krishnan; V M Ramakrishnan; L R Clayton; S K Williams; J B Hoying; N L Boyd
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

6.  The Epicardium and the Development of the Atrioventricular Junction in the Murine Heart.

Authors:  Marie M Lockhart; Aimee L Phelps; Maurice J B van den Hoff; Andy Wessels
Journal:  J Dev Biol       Date:  2014-03-01

7.  Transcriptional Control of Cell Lineage Development in Epicardium-Derived Cells.

Authors:  Caitlin M Braitsch; Katherine E Yutzey
Journal:  J Dev Biol       Date:  2013-07-03

Review 8.  The role of endothelial-to-mesenchymal transition in cancer progression.

Authors:  S Potenta; E Zeisberg; R Kalluri
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.